

News

FOR IMMEDIATE RELEASE:

Cerestim appoints expert advisors.

London, UK – July 14th, 2014 – Cerestim Ltd is pleased to announce that it has appointed expert advisers to provide guidance on regulatory, IP, health economics, tax and fund raising.

Emergo (<http://www.emergogroup.com/>) have been appointed as regulatory consultants. They will assist with the determination of the regulatory pathway.

Adams Business Associates (<http://aba-business.com/>) have been appointed to evaluate the economic case for the use of transcranial electrical stimulation in the remediation of treatment resistant depression.

Dr David Raybone of Animas Consulting has been appointed to provide expert advice with IP mapping and prosecution.

Confluence (<http://www.confluencetax.com/>) have been retained to assist with the tax aspects of fund raising.

Dr Stephen Parker of sp2 Consulting has been engaged to advise on fund raising.

Dr Andy Blackwell has been retained as a consultant to advise on clinical & marketing pathways and IP.

Ian Harris CEO said "I am delighted to work with this leading group of experts to leverage their knowledge and skills to develop the exciting Cerestim proposition".

Cerestim is engaged in developing its scientific and commercialisation strategy; fund raising; developing academic and commercial partners and preparing IP. It started a study in July 'Feasibility assessment of the opportunity for the use of transcranial cranial stimulation for the treatment of brain disorders'. This is part funded by the Technology Strategy Board.

Contact:

Ian Harris, Cerestim
ian.harris@cerestim.com

###